



Supplemental Figures for:

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women with Early Stage Breast Cancer
Norah Lynn Henry et al.

Figure S1A






Positive mean change in EuroQOL indicates improvement from baseline. Mean (SD) baseline EuroQOL scores are exemestane = 84.54 (11.54); letrozole = 83.07 (13.46), p=0.46. P-value by Wilcoxon Test; * - statistically significant. EuroQOL VAS = visual analogue scale (range 0-100, 100 indicating best imaginable health state); SD = standard deviation.



Supplemental Figures for:

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women with Early Stage Breast Cancer
Norah Lynn Henry et al.

Figure S1B:



Positive mean change in CES-D indicates worsening from baseline. Mean (SD) baseline CES-D scores are exemestane = 8.25 (7.77); letrozole = 8.19 (7.42), p=0.90. P-value by Wilcoxon Test; * - statistically significant, CES-D = Centers for Epidemiologic Studies Depression Scale (range 0-60; \geq 16 suggests clinical depression); SD = standard deviation.




Supplemental Figures for:

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women with Early Stage Breast Cancer
Norah Lynn Henry et al.

Figure S1C:

Mean Change from Baseline in HADSA by Drug



Time (Months)

| No. Evaluable by month: | | 1 | 3 | 6 | 12 | 24 |
|-------------------------|-----|-----|-----|-----|-----|-----|
| Exemestane | 243 | | | | | |
| | | 231 | 212 | 186 | | 122 |
| | | | | | 152 | |
| Letrozole | 247 | 236 | 218 | 206 | 179 | 153 |

Positive mean change in HADS-A indicates worsening from baseline. Mean (SD) baseline HADS-A scores are exemestane = 4.22 (3.30); letrozole = 4.03 (3.07), p=0.59. P-value by Wilcoxon Test. HADS-A = The Hospital Anxiety and Depression Scale-Anxiety (range 0-21; \geq 8 suggests clinical anxiety); SD = standard deviation